Issues in antifungal susceptibility testing
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
In line with the availability of an increasing array of systemic antifungal agents, there is a need for accurate, reproducible and predictive susceptibility testing of fungal isolates in order to help inform clinical choice. Much early attention on antifungal susceptibility testing focused on defining test parameters that produced reproducible and reliable intra- and inter-laboratory results and there are now standardized methods for the testing of yeast and mould isolates. The application of this standardized approach produces susceptibility results that are comparable between laboratories and allow epidemiological analyses at the national and even international level. In addition, monitoring and prediction of emerging susceptibility trends are now possible. As methodology improved, attention shifted to clinical outcome data in order to establish breakpoints for antifungal agents. However, there are a large number of confounding factors that must be considered when trying to assess the in vivo activity of antifungal agents in invasive disease. An approach based on defining normal susceptibility ranges, together with pharmacokinetic and pharmacodynamic analyses and identification of resistance mechanisms, has helped to establish breakpoint data for at least some of the systemic agents active against yeast isolates. Moreover, for some drugs, there is a supporting in vitro-in vivo correlation available from studies of clinical efficacy. Application of susceptibility testing has helped to define the spectrum of activity of all the currently available antifungal agents. Both intrinsic and emergent antifungal drug resistance are encountered and the predictability of innate resistance has meant that species identification is often sufficient to alert the clinician to the likelihood of in vitro and often-associated in vivo resistance. Currently, emergence of resistance in a previously susceptible strain during a course of treatment remains rare.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 4×
“7% of all clinical isolates of Candida spp.(8)”
BackgroundMethodInfluentialComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601 · cited 1×
“parapsilosis is associated with a lower mortality rate than other yeast species and may therefore be a weaker pathogen and easier to eradicate.(30,31) It is clear that although breakpoints for susceptibility to the echinocandins have yet to be established, any proposed susceptibility cut-off point should encompass the…”
BackgroundTortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509 · cited 1×
“parapsilosis is associated with a lower mortality rate than other yeast species and may therefore be a weaker pathogen and easier to eradicate.(30,31) It is clear that although breakpoints for susceptibility to the echinocandins have yet to be established, any proposed susceptibility cut-off point should encompass the…”
BackgroundPfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · cited 1×
“There are also in vivo data supporting an interpretive breakpoint for voriconazole, although not as yet for posaconazole.(24) Currently, validated breakpoints include those for fluconazole, itraconazole, flucytosine and voriconazole.”
BackgroundSelf-citationMechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis
Bennett, J. E., Izumikawa, K., & Marr, K. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1773-1777.2004 · Cited by 217 · cited 3×
“glabrata that often demonstrates either innate or rapidly emergent resistance due to up-regulation of CDR drug efflux pumps.(36) Scatterplots of voriconazole or posaconazole MICs versus fluconazole MICs for C.”
BackgroundInfluentialPark, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113 · cited 1×
“do not appear to correlate with treatment failure or success, suggesting that factors other than MIC may have a greater impact on the outcome of invasive candidosis.(27) Breakpoints for the echinocandin class of agents have yet to be established due largely to the dearth of resistant isolates for analysis.”
BackgroundLY303366 Exhibits Rapid and Potent Fungicidal Activity in Flow Cytometric Assays of Yeast Viability
Green, L. J., Marder, P., Mann, L. L., Chio, L.-C., & Current, W. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.830 · Cited by 57
Cited by
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Heo, S. T., Tatara, A. M., Jiménez-Ortigosa, C., Jiang, Y., Lewis, R. E., Tarrand, J., Tverdek, F., Albert, N. D., Verweij, P. E., Meis, J. F., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix297 · Cited by 67
Metadata
- Authors
- Johnson, E. M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01-01
- Volume
- 61
- Issue
- Supplement 1
- Pages
- i13-i18
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2138186956
- Cited by
- 70
- References
- 10
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.